
Russell C Dale

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3590314/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi–Goutières syndrome. Developmental Medicine and Child Neurology, 2022, 64, 266-271.	1.1	12
2	Emerging evidence of Toll-like receptors as a putative pathway linking maternal inflammation and neurodevelopmental disorders in human offspring: A systematic review. Brain, Behavior, and Immunity, 2022, 99, 91-105.	2.0	11
3	Autosomal dominant ADAR c.3019G>A (p.(G1007R)) variant is an important mimic of hereditary spastic paraplegia and cerebral palsy. Brain and Development, 2022, 44, 153-160.	0.6	3
4	Development of a translational inflammation panel for the quantification of cerebrospinal fluid Pterin, Tryptophan-Kynurenine and Nitric oxide pathway metabolites. EBioMedicine, 2022, 77, 103917.	2.7	11
5	Rapid onset functional ticâ€like behaviours in children and adolescents during <scp>COVID</scp> â€19: Clinical features, assessment and biopsychosocial treatment approach. Journal of Paediatrics and Child Health, 2022, 58, 1181-1187.	0.4	37
6	Acute encephalopathy with biphasic seizures and restricted diffusion. Journal of Paediatrics and Child Health, 2022, 58, 1688-1690.	0.4	4
7	Delivering paediatric precision medicine: Genomic and environmental considerations along the causal pathway of childhood neurodevelopmental disorders. Developmental Medicine and Child Neurology, 2022, 64, 1077-1084.	1.1	7
8	Maternal immune-related conditions during pregnancy may be a risk factor for neuropsychiatric problems in offspring throughout childhood and adolescence. Psychological Medicine, 2021, 51, 2904-2914.	2.7	15
9	Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	58
10	Cerebrospinal fluid metabolites in tryptophanâ€kynurenine and nitric oxide pathways: biomarkers for acute neuroinflammation. Developmental Medicine and Child Neurology, 2021, 63, 552-559.	1.1	15
11	Psychiatric comorbidity is common in dystonia and other movement disorders. Archives of Disease in Childhood, 2021, 106, 62-67.	1.0	4
12	Association of Maternal Autoimmune Disease With Attention-Deficit/Hyperactivity Disorder in Children. JAMA Pediatrics, 2021, 175, e205487.	3.3	34
13	Maternal autoimmunity and inflammation are associated with childhood tics and obsessive-compulsive disorder: Transcriptomic data show common enriched innate immune pathways. Brain, Behavior, and Immunity, 2021, 94, 308-317.	2.0	32
14	Opsoclonusâ€myoclonus in Aicardiâ€Goutières syndrome. Developmental Medicine and Child Neurology, 2021, 63, 1483-1486.	1.1	4
15	Maternal immune activation and neuroinflammation in human neurodevelopmental disorders. Nature Reviews Neurology, 2021, 17, 564-579.	4.9	222
16	Rapid Onset Functional Ticâ€Like Behaviors in Young Females During the <scp>COVID</scp> â€19 Pandemic. Movement Disorders, 2021, 36, 2707-2713.	2.2	85
17	505Maternal autoimmune disease and increased attention deficit/hyperactivity disorder among offspring: A cohort study and meta-analysis. International Journal of Epidemiology, 2021, 50, .	0.9	0
18	Cerebrospinal fluid free light chain quantitation is a specific biomarker for inflammatory neurological disorders in a paediatric patient cohort. Pathology, 2021, 53, 753-758.	0.3	0

RUSSELL C DALE

#	Article	IF	CITATIONS
19	Cerebrospinal fluid metabolomics: detection of neuroinflammation in human central nervous system disease. Clinical and Translational Immunology, 2021, 10, e1318.	1.7	30
20	Maternal acute and chronic inflammation in pregnancy is associated with common neurodevelopmental disorders: a systematic review. Translational Psychiatry, 2021, 11, 71.	2.4	158
21	Maternal immune conditions are increased in males with autism spectrum disorders and are associated with behavioural and emotional but not cognitive co-morbidity. Translational Psychiatry, 2020, 10, 286.	2.4	40
22	Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmuneâ€associated epilepsy: Conceptual definitions. Epilepsia, 2020, 61, 1341-1351.	2.6	138
23	Effects of the Positive Threshold and Data Analysis on Human MOG Antibody Detection by Live Flow Cytometry. Frontiers in Immunology, 2020, 11, 119.	2.2	7
24	Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	178
25	Etiology is the key determinant of neuroinflammation in epilepsy: Elevation of cerebrospinal fluid cytokines and chemokines in febrile infectionâ€related epilepsy syndrome and febrile status epilepticus. Epilepsia, 2019, 60, 1678-1688.	2.6	81
26	Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. Acta Neuropathologica Communications, 2019, 7, 145.	2.4	71
27	Maternal thyroid autoimmunity associated with acuteâ€onset neuropsychiatric disorders and global regression in offspring. Developmental Medicine and Child Neurology, 2019, 61, 984-988.	1.1	12
28	Therapeutic plasma exchange in paediatric neuroimmunology: some evidence but more is needed. Developmental Medicine and Child Neurology, 2019, 61, 504-505.	1.1	1
29	Mycophenolate mofetil in paediatric autoimmune or immuneâ€mediated diseases of the central nervous system: clinical experience and recommendations. Developmental Medicine and Child Neurology, 2019, 61, 458-468.	1.1	15
30	Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibodyâ€associated demyelination in children. Developmental Medicine and Child Neurology, 2019, 61, 610-614.	1.1	51
31	Magnetic resonance imaging in enterovirusâ€71, myelin oligodendrocyte glycoprotein antibody, aquaporinâ€4 antibody, and multiple sclerosisâ€associated myelitis in children. Developmental Medicine and Child Neurology, 2019, 61, 1108-1116.	1.1	22
32	Mycophenolate mofetil, azathioprine and methotrexate usage in paediatric anti-NMDAR encephalitis: A systematic literature review. European Journal of Paediatric Neurology, 2019, 23, 7-18.	0.7	17
33	An open-label trial of JAK 1/2 blockade in progressive <i>IFIH1</i> -associated neuroinflammation. Neurology, 2018, 90, 289-291.	1.5	60
34	Principles and approaches to the treatment of immune-mediated movement disorders. European Journal of Paediatric Neurology, 2018, 22, 292-300.	0.7	24
35	Seizure outcome after corpus callosotomy in a large paediatric series. Developmental Medicine and Child Neurology, 2018, 60, 199-206.	1.1	23
36	Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 127-137.	0.9	422

RUSSELL C DALE

#	Article	IF	CITATIONS
37	Glutamate receptor δ2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome. Neurology, 2018, 91, e714-e723.	1.5	43
38	The Immune System, Cytokines, and Biomarkers in Autism Spectrum Disorder. Neuroscience Bulletin, 2017, 33, 194-204.	1.5	182
39	Genetic, Phenotypic, and Interferon Biomarker Status in ADAR1-Related Neurological Disease. Neuropediatrics, 2017, 48, 166-184.	0.3	62
40	Cerebrospinal fluid cyto″chemokine profile during acute herpes simplex virus induced antiâ€ <i>N</i> â€methylâ€ <scp>d</scp> â€aspartate receptor encephalitis and in chronic neurological sequelae. Developmental Medicine and Child Neurology, 2017, 59, 806-814.	1.1	20
41	Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges. Current Opinion in Neurology, 2017, 30, 334-344.	1.8	80
42	High sensitivity and specificity in proposed clinical diagnostic criteria for antiâ€ <i>N</i> â€methylâ€ <scp>D</scp> â€aspartate receptor encephalitis. Developmental Medicine and Child Neurology, 2017, 59, 1256-1260.	1.1	46
43	Immunotherapeutics in Pediatric Autoimmune Central Nervous System Disease: Agents and Mechanisms. Seminars in Pediatric Neurology, 2017, 24, 214-228.	1.0	5
44	Utility of CSF Cytokine/Chemokines as Markers of Active Intrathecal Inflammation: Comparison of Demyelinating, Anti-NMDAR and Enteroviral Encephalitis. PLoS ONE, 2016, 11, e0161656.	1.1	102
45	Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and longâ€ŧerm outcome. Developmental Medicine and Child Neurology, 2016, 58, 1180-1192.	1.1	30
46	Treatment Choices in Optic Neuritis: Corticosteroids, Intravenous Immunoglobulin, Plasma Exchange, or Other?. Neuropediatrics, 2016, 47, 137-138.	0.3	1
47	Postencephalitic epilepsy and drugâ€resistant epilepsy after infectious and antibodyâ€associated encephalitis in childhood: Clinical and etiologic risk factors. Epilepsia, 2016, 57, e7-e11.	2.6	54
48	Symptomatic treatment of children with antiâ€NMDAR encephalitis. Developmental Medicine and Child Neurology, 2016, 58, 376-384.	1.1	60
49	Clinical Characteristics and Functional Motor Outcomes of Enterovirus 71 Neurological Disease in Children. JAMA Neurology, 2016, 73, 300.	4.5	106
50	A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology, The, 2016, 15, 391-404.	4.9	2,782
51	Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmunity Reviews, 2016, 15, 307-324.	2.5	229
52	CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: A systematic review. Cytokine, 2016, 77, 227-237.	1.4	209
53	Autoimmune Movement Disorders in Children: Clinical Characteristics and Therapeutic Considerations. Journal of Pediatric Neurology, 2015, 13, 144-154.	0.0	0
54	Characterization of human disease phenotypes associated with mutations in <i>TREX1</i> , <i>RNASEH2A</i> , <i>RNASEH2B</i> , <i>RNASEH2C</i> , <i>SAMHD1</i> , <i>ADAR</i> , and <i>IFIH1</i> . American Journal of Medical Genetics, Part A, 2015, 167, 296-312.	0.7	447

RUSSELL C DALE

#	Article	IF	CITATIONS
55	Infectious and Autoantibody-Associated Encephalitis: Clinical Features and Long-term Outcome. Pediatrics, 2015, 135, e974-e984.	1.0	115
56	Immune therapy in autoimmune encephalitis: a systematic review. Expert Review of Neurotherapeutics, 2015, 15, 1391-1419.	1.4	168
57	Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e12.	3.1	158
58	Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e40.	3.1	192
59	Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology, 2014, 83, 142-150.	1.5	275
60	International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Multiple Sclerosis Journal, 2013, 19, 1261-1267.	1.4	883
61	Autoimmune epilepsy in children: Case series and proposed guidelines for identification. Epilepsia, 2013, 54, 1036-1045.	2.6	76
62	Autoantibody-Associated Movement Disorders. Neuropediatrics, 2013, 44, 336-345.	0.3	28
63	Cerebrospinal fluid Bâ€cell expansion in longitudinally extensive transverse myelitis associated with neuromyelitis optica immunoglobulin G. Developmental Medicine and Child Neurology, 2011, 53, 856-860.	1.1	9
64	Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Annals of Neurology, 2009, 66, 833-842.	2.8	283
65	Cerebrospinal fluid neopterin in paediatric neurology: a marker of active central nervous system inflammation. Developmental Medicine and Child Neurology, 2009, 51, 317-323.	1.1	85